exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089255 RNA Name: hsa-miR-629-5p RNA Type: miRNA Chromosome: chr15 Starnd: - Coordinate: Start Site(bp): 70079427 End Site(bp): 70079447 External Links: hsa-miR-629-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BAZ2A chr12 56595596 56636816 - CBX2 chr17 79778148 79787983 + CBX3 chr7 26201162 26213607 + COL4A1 chr13 110148963 110307157 - DENND5B chr12 31382226 31591136 - GRB10 chr7 50590063 50793462 - HDLBP chr2 241227264 241317061 - LDLR chr19 11089462 11133820 + MCM3 chr6 52264014 52284881 - MSI1 chr12 120341330 120369164 - NOLC1 chr10 102152176 102163871 + PA2G4 chr12 56104537 56113910 + PHF12 chr17 28905250 28951771 - PRR12 chr19 49591182 49626439 + RSU1 chr10 16590611 16817463 - SH3KBP1 chrX 19533977 19887600 - SH3PXD2A chr10 103594027 103855543 - TULP4 chr6 158232236 158511828 + UBN2 chr7 139230356 139308236 + WIPF2 chr17 40219304 40284136 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0001230 chr22 38895404 38897285 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC021078.1 chr5 149494314 149504670 - NEAT1 chr11 65422774 65445540 + U62317.3 chr22 50597152 50597599 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.